Skip to content
10-Q

Quarterly Report

Processa Pharmaceuticals, Inc. PCSA

0001493152-25-011685

← back to feed
Filed
Aug 7, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q2 2025 · Aug 5, 2025 50.35M sh
Shares Diluted Q2 2025 · Jun 30, 2025 15.57M sh
Shares Diluted Q2 2025 · Jun 30, 2025 12.4M sh
Shares Diluted Q2 2025 · Jun 30, 2024 2.98M sh
Shares Diluted Q2 2025 · Jun 30, 2024 2.72M sh
Operating Cash Flow Q2 2025 · Jun 30, 2025 −$5M
Operating Cash Flow Q2 2025 · Jun 30, 2024 −$5.39M
Cash And Equivalents Q2 2025 · Jun 30, 2025 $6.94M
Cash And Equivalents Q2 2025 · Dec 31, 2024 $1.19M
Stockholders Equity Q2 2025 · Jun 30, 2025 $6.11M
Stockholders Equity Q2 2025 · Mar 31, 2025 $3.53M
Stockholders Equity Q2 2025 · Dec 31, 2024 $1.7M
Stockholders Equity Q2 2025 · Jun 30, 2024 $6.02M
Stockholders Equity Q2 2025 · Mar 31, 2024 $8.88M
Stockholders Equity Q2 2025 · Dec 31, 2023 $4.99M
Current Liabilities Q2 2025 · Jun 30, 2025 $2.07M
Current Liabilities Q2 2025 · Dec 31, 2024 $1.53M
Total Liabilities Q2 2025 · Jun 30, 2025 $2.07M
Total Liabilities Q2 2025 · Dec 31, 2024 $1.53M
Current Assets Q2 2025 · Jun 30, 2025 $7.15M
Current Assets Q2 2025 · Dec 31, 2024 $1.87M
Total Assets Q2 2025 · Jun 30, 2025 $8.18M
Total Assets Q2 2025 · Dec 31, 2024 $3.23M
Eps Diluted Q2 2025 · Jun 30, 2025 −$0.25
Eps Diluted Q2 2025 · Jun 30, 2025 −$0.55
Eps Diluted Q2 2025 · Jun 30, 2024 −$1.01
Eps Diluted Q2 2025 · Jun 30, 2024 −$2.11
Eps Basic Q2 2025 · Jun 30, 2025 −$0.25
Eps Basic Q2 2025 · Jun 30, 2025 −$0.55
Eps Basic Q2 2025 · Jun 30, 2024 −$1.01
Eps Basic Q2 2025 · Jun 30, 2024 −$2.11
Net Income Q2 2025 · Jun 30, 2025 −$3.93M
Net Income Q2 2025 · Jun 30, 2025 −$6.77M
Net Income Q2 2025 · Mar 31, 2025 −$2.83M
Net Income Q2 2025 · Jun 30, 2024 −$3.01M
Net Income Q2 2025 · Jun 30, 2024 −$5.74M
Net Income Q2 2025 · Mar 31, 2024 −$2.73M
Operating Income Q2 2025 · Jun 30, 2025 −$3.95M
Operating Income Q2 2025 · Jun 30, 2025 −$6.8M
Operating Income Q2 2025 · Jun 30, 2024 −$3.08M
Operating Income Q2 2025 · Jun 30, 2024 −$5.89M